Accordingly, in mouse models, genetic ablation, or pharmacological inhibition of FABP4 protects against atherosclerosis and type 2 diabetes by a mechanism involving PPARγ activation, which antagonizes NF-κB-dependent cytokine production [30, 79, 80]. Here, PPARG is linked to type 2 diabetes mellitus.